Kyowa Kirin

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

News

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Spain has agreed to reimburse Orchard Therapeutics' ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy.

News

Orchard will help Kyowa Kirin grow in gene therapy

Japan’s Kyowa Kirin has reached an agreement to buy Orchard Therapeutics of the UK in a deal valued at up to $478 million, ahead of an FDA decision on the biotech’s lead g

News

Grünenthal buys into Kyowa Kirin's mature medicines portfoli...

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kura scores FDA okay for rival to Syndax's leukaemia drug

How pharma is tackling new direct-to-patient programmes

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Orchard will help Kyowa Kirin grow in gene therapy

Grünenthal buys into Kyowa Kirin's mature medicines portfoli...

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Using AI-driven synthetic personas to take your insights fur...

Kyowa Kirin

Editor's Picks